Fukuda Denshi (6960) Fundamentals 2026 — P/E 16.8x, Revenue Analysis | SniperIQ
Fukuda Denshi (6960) is a JP-listed Healthcare company in Medical - Devices with a market capitalization of ¥310.4B, trading at ¥11490.00 on the JPX. This SniperIQ fundamentals page covers Fukuda Denshi's valuation (P/E 16.8x, P/B 1.7x), profitability (net margin 13.5%), revenue (¥139.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Fukuda Denshi's market cap?
Fukuda Denshi (6960) has a market capitalization of approximately ¥310.4B, trading at ¥11490.00 on the JPX. Market cap moves with the live share price.
What is Fukuda Denshi's P/E ratio?
Fukuda Denshi's trailing twelve-month P/E ratio is 16.8x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Fukuda Denshi?
Fukuda Denshi runs a net profit margin of 13.5%, a gross margin of 54.8%, and an operating margin of 19.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Fukuda Denshi generate?
Fukuda Denshi reported revenue of ¥139.7B for fiscal year 2025, with net income of ¥18.8B and earnings per share (EPS) of 683.38. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Fukuda Denshi pay a dividend?
Fukuda Denshi offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Fukuda Denshi financially healthy?
Fukuda Denshi carries a debt-to-equity ratio of 0.02x and a current ratio of 3.88x, with a market beta of 0.61. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Fukuda Denshi a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fukuda Denshi (6960) the key facts are: market cap ¥310.4B, P/E 16.8x, revenue ¥139.7B, 52-week range 6560-12490. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Fukuda Denshi's full fundamentals live
Get Fukuda Denshi's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.